RT Journal Article
SR Electronic
T1 Modeling the spread of Covid-19 under active management
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.20.20235903
DO 10.1101/2020.11.20.20235903
A1 Ivan Cherednik
YR 2020
UL http://medrxiv.org/content/early/2020/11/24/2020.11.20.20235903.abstract
AB Classical approaches to modeling the spread of epidemics are based on two assumptions: the exponential growth of the total number of infections and the saturation due to the herd immunity. With Covid-19, the growth is essentially power-type, especially during the middle stages, and the saturation is currently mostly due to the protective measures. Focusing on these features and the role of epidemic management, we obtain differential equations for the total number of detected cases of Covid-19, which describe the actual curves in many countries almost with the accuracy of physics laws. The two-phase solution we propose worked very well almost for the whole periods of the spread practically in all countries we analyzed that reached the saturation during the first waves. Bessel functions play the key role in our approach. Due to a very small number of parameters, namely, the initial transmission rate and the intensity of the hard and soft measures, we obtain a convincing explanation of the surprising uniformity of the curves of the total numbers of detected infections in many different areas. This theory can serve as a tool for forecasting the epidemic spread and evaluating the efficiency of the protective measures, which is very much needed for epidemics. As its practical application, the computer programs aimed at providing projections for late stages of Covid-19 proved to be remarkably stable in many countries, including Western Europe, the USA and some in Asia.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementPartial support by NSF grant DMS-1901796 and the Simons Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval is necessaryAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMostly in the work "A surprising formula for the spread of Covid-19 under aggressive management" https://www.medrxiv.org/content/10.1101/2020.04.29.20084483v5